Consortium for HIV/AIDS Vaccine Development
Consortium for HIV/AIDS Vaccine Development
批准号:
10664947
负责人:
Dennis R. Burton
金额:
$3020.48万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-07-01 至 2026-06-30
关键词:
Animal ModelAnimalsAntibodiesAntibody ResponseAntigensBiological AssayCellsClinical TrialsDedicationsDevelopmentExposure toFutureGlycoproteinsGoalsHIVHIV InfectionsHIV Vaccine Trials NetworkHIV envelope proteinHIV vaccineHumanImmunoglobulin Somatic HypermutationImmunologicsIndividualInfectionMucous MembranePhase I Clinical TrialsPre-Clinical ModelProceduresRegimenResearch SupportSamplingSeriesSiteStructureTechnologyTestingTranslatingVaccinesVirionVirusdesignexperienceflexibilityin vivoinnovationmanufacturemouse modelneutralizing antibodynonhuman primatenoveloperationpre-clinicalproduct developmentprogramsprotective efficacyresearch clinical testingsuccesstranslational goalvaccination strategyvaccine development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract (30 lines)
The overarching goal of this CHAVD is to develop a sequential HIV vaccine regimen that
induces sustained protective levels of broadly neutralizing antibodies (bnAbs) in humans. bnAbs
provide complete protection against HIV infection in preclinical models. We hypothesize that an
effective HIV vaccine will need to consistently induce bnAbs against 2-3 different sites on the
HIV Envelope glycoprotein (Env) of the virus in most (>90%) of vaccine recipients. Targeting
multiple sites is necessary to provide adequate coverage against the huge diversity of global
isolates. We propose a sequential strategy in which a series of designed immunogens guide
antibody responses from precursors to bnAbs. We are intensely developing and testing
immunogens. We have shown proof-of-principle of the sequential strategy in preclinical models
and our first three immunogens are entering manufacturing or clinical trials shortly.
The second major goal of this CHAVD is to generate immunogens that induce protective non-
neutralizing antibody (nnAb) responses that can either act alone or augment the protective
activity of bnAb responses. To accomplish this goal, we propose a tiered approach in which the
ability of nnAbs to capture infectious virions and to clear infected cells in vivo in two established
mouse models will be explored. The most effective nnAbs, alone and in combination with other
nnAbs and bnAbs, will then be assessed for their ability to protect nonhuman primates against
virus challenge. Protective nnAbs will be used as templates for immunogen design.
To support our translational effort, we have organized state-of the-art Manufacturing, Clinical
Trials Sample Analysis and Management and Operations units. In addition, we have established
twelve Scientific Research Support Units, headed by leaders in their fields, to underpin the
diverse scientific and technical capabilities required to execute our comprehensive and highly
integrated vaccine program
Finally, this CHAVD proposal is built upon a highly successful, innovative and efficient CHAVI-
ID program that has made major scientific contributions to the HIV vaccine field. The CHAVD
provides the opportunity to advance and translate these contributions into an HIV vaccine.
期刊论文(33)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.jmb.2021.167303
发表时间:
2021-12-03
期刊:
Journal of molecular biology
影响因子:
5.6
作者:
[Omorodion O, Wilson IA]
通讯作者:
Wilson IA
Introductory article for Immunological Reviews, Vol 310.
《免疫学评论》的介绍性文章,第 310 卷。
DOI:
10.1111/imr.13128
发表时间:
2022
期刊:
Immunological reviews
影响因子:
8.7
作者:
[Burton,DennisR, Feinberg,MarkB]
通讯作者:
Feinberg,MarkB
DOI:
10.1101/2021.03.08.433764
发表时间:
2021-03
期刊:
bioRxiv
影响因子:
--
作者:
[Joel D. Allen;H. Chawla;Firdaus Samsudin;Lorena Zuzic;A. T. Shivgan;Yasunori Watanabe;Wan-ting He;Sean Callaghan;G. Song;Peter Yong;P. Brouwer;Yutong Song;Yongfei Cai;Helen M. E. Duyvesteyn;T. Malinauskas;J. Kint;P. Pino;Maria J. Wurm;M. Frank;Bing Chen;D. Stuart;R. Sanders;R. Andrabi;D. Burton;Sai Li;P. Bond;M. Crispin]
通讯作者:
Joel D. Allen;H. Chawla;Firdaus Samsudin;Lorena Zuzic;A. T. Shivgan;Yasunori Watanabe;Wan-ting He;Sean Callaghan;G. Song;Peter Yong;P. Brouwer;Yutong Song;Yongfei Cai;Helen M. E. Duyvesteyn;T. Malinauskas;J. Kint;P. Pino;Maria J. Wurm;M. Frank;Bing Chen;D. Stuart;R. Sanders;R. Andrabi;D. Burton;Sai Li;P. Bond;M. Crispin
Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells.
DOI:
10.1038/s41541-021-00376-7
发表时间:
2021-09-06
期刊:
NPJ vaccines
影响因子:
9.2
作者:
[Lee JH, Toy L, Kos JT, Safonova Y, Schief WR, Havenar-Daughton C, Watson CT, Crotty S]
通讯作者:
Crotty S
DOI:
10.1016/j.isci.2022.104914
发表时间:
2022-09-16
期刊:
ISCIENCE
影响因子:
5.8
作者:
[Zhao, Fangzhu, Keating, Celina, Ozorowski, Gabriel, Shaabani, Namir, Francino-Urdaniz, Irene M., Barman, Shawn, Limbo, Oliver, Burns, Alison, Zhou, Panpan, Ricciardi, Michael J., Woehl, Jordan, Tran, Quoc, Turner, Hannah L., Peng, Linghang, Huang, Deli, Nemazee, David, Andrabi, Raiees, Sok, Devin, Teijaro, John R., Whitehead, Timothy A., Ward, Andrew B., Burton, Dennis R., Jardine, Joseph G.]
通讯作者:
Jardine, Joseph G.
共 21 条
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antivirals
-
批准号:10186653
-
项目类别:
-
资助金额:$81.69万
-
财政年份:2020
-
负责人:Dennis R. Burton
-
依托单位:
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antivirals
-
批准号:10267406
-
项目类别:
-
资助金额:$63.56万
-
财政年份:2020
-
负责人:Dennis R. Burton
-
依托单位:
Consortium for HIV/AIDS Vaccine Development
-
批准号:10440394
-
项目类别:
-
资助金额:$3980.87万
-
财政年份:2019
-
负责人:Dennis R. Burton
-
依托单位:
Consortium for HIV/AIDS Vaccine Development
-
批准号:10188408
-
项目类别:
-
资助金额:$3285.31万
-
财政年份:2019
-
负责人:Dennis R. Burton
-
依托单位:
Development of immunology and immunization strategies that induce broadly pro
-
批准号:9089825
-
项目类别:
-
资助金额:$1872.06万
-
财政年份:2016
-
负责人:Dennis R. Burton
-
依托单位:
Development of immunology and immunization strategies that induce broadly pro
-
批准号:9316758
-
项目类别:
-
资助金额:$24.02万
-
财政年份:2016
-
负责人:Dennis R. Burton
-
依托单位:
Genomic modification with purified nuclease proteins for HIV-1 therapy
-
批准号:9267454
-
项目类别:
-
资助金额:$77.96万
-
财政年份:2014
-
负责人:Dennis R. Burton
-
依托单位:
Genomic modification with purified nuclease proteins for HIV-1 therapy
-
批准号:9058517
-
项目类别:
-
资助金额:$77.96万
-
财政年份:2014
-
负责人:Dennis R. Burton
-
依托单位:
Genomic modification with purified nuclease proteins for HIV-1 therapy
-
批准号:8930950
-
项目类别:
-
资助金额:$79.26万
-
财政年份:2014
-
负责人:Dennis R. Burton
-
依托单位:
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery
-
批准号:8508849
-
项目类别:
-
资助金额:$2210.02万
-
财政年份:2012
-
负责人:Dennis R. Burton
-
依托单位:
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery
-
批准号:8330361
-
项目类别:
-
资助金额:$1576.09万
-
财政年份:2012
-
负责人:Dennis R. Burton
-
依托单位:
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery
-
批准号:8681335
-
项目类别:
-
资助金额:$1955.58万
-
财政年份:2012
-
负责人:Dennis R. Burton
-
依托单位:
MUCOSAL SECRETION KINETICS OF THE PG9 BROADLY NEUTRALIZING ANTIBODY AGAINST HIV
-
批准号:8358246
-
项目类别:
-
资助金额:$1.31万
-
财政年份:2011
-
负责人:Dennis R. Burton
-
依托单位:
ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1
-
批准号:8358236
-
项目类别:
-
资助金额:$23.83万
-
财政年份:2011
-
负责人:Dennis R. Burton
-
依托单位:
Mechanisms of Antibody Interception of Virus Following SHIV Challenge
-
批准号:8198150
-
项目类别:
-
资助金额:$39.06万
-
财政年份:2011
-
负责人:Dennis R. Burton
-
依托单位:
Multifunctional Human Anti-HIV Antibodies
-
批准号:8619582
-
项目类别:
-
资助金额:$47.38万
-
财政年份:2011
-
负责人:Dennis R. Burton
-
依托单位:
ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1
-
批准号:8173157
-
项目类别:
-
资助金额:$5.16万
-
财政年份:2010
-
负责人:Dennis R. Burton
-
依托单位:
Probing the antibody response to HCV to facilitate rational immunogen design
-
批准号:8004975
-
项目类别:
-
资助金额:$61.88万
-
财政年份:2009
-
负责人:Dennis R. Burton
-
依托单位:
Probing the antibody response to HCV to facilitate rational immunogen design
-
批准号:7580876
-
项目类别:
-
资助金额:$62.68万
-
财政年份:2009
-
负责人:Dennis R. Burton
-
依托单位:
Probing the antibody response to HCV to facilitate rational immunogen design
-
批准号:7753182
-
项目类别:
-
资助金额:$61.5万
-
财政年份:2009
-
负责人:Dennis R. Burton
-
依托单位:
海外基金